March 25, 2021 Greenbriar Equity Group has soared past its $1bn Fund V target to reach a $1.68bn final close for the fund, after just a few months of entirely virtual fundraising.
AltAssets has been serving the global private equity industry for over a decade and has become established as a trusted source of independent news and views on the industry by thousands of professionals worldwide.
Los Angeles County Employees Retirement Association is planning to launch a request for proposal for a private equity consultant before the end of January.
March 31, 2021 Distressed investment specialist Cerberus Capital Management has hit a $2.8bn final close for its latest flagship opportunistic real estate fund.
AltAssets has been serving the global private equity industry for over a decade and has become established as a trusted source of independent news and views on the industry by thousands of professionals worldwide.
Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor
February 19, 2021
Regor Therapeutics, a clinical-stage biotech company with operations in China and the US, has secured $90 million in a Series B round of financing led by the biomedical venture capital (VC) firm Lilly Asia Ventures (LAV).
The new round saw participation from investors including China-focused private equity (PE) firm Loyal Valley Capital (LVC); cross-border, pharmaceutical-focused PE Lanting Capital (LVC); TF Capital, which primarily invests in early-stage life sciences startups; and Vertex Ventures China.
Chinese drug maker Qilu Pharmaceutical Group had backed Regor’s Series A round.
Founded in July 2018, Regor specialises in the discovery and delivery of clinically differentiated, best- and first-in-class drugs for patients globally to treat cancer, immune disorders, and metabolic diseases.